Silence Therapeutics Plc (SLNCF)
4.00
0.00 (0.00%)
USD |
OTCM |
Sep 04, 16:00
Silence Therapeutics Research and Development Expense (Quarterly) : 8.297M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 8.297M |
| March 31, 2026 | 8.359M |
| December 31, 2025 | 8.919M |
| September 30, 2025 | 17.96M |
| June 30, 2025 | 15.28M |
| March 31, 2025 | 18.13M |
| September 30, 2024 | 19.90M |
| June 30, 2024 | 13.87M |
| March 31, 2024 | 9.35M |
| Date | Value |
|---|---|
| December 31, 2023 | 12.33M |
| September 30, 2023 | 11.29M |
| June 30, 2023 | 15.79M |
| March 31, 2023 | 15.22M |
| December 31, 2022 | 9.851M |
| September 30, 2022 | 10.31M |
| June 30, 2022 | 13.58M |
| March 31, 2022 | 10.19M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | 3.020M |
| Mereo BioPharma Group Plc | 1.811M |
| Compass Pathways Plc | 29.23M |
| HemoGenyx Pharmaceuticals Plc | -- |